DİSLİPİDEMİ VE COVİD 19 ENFEKSİYON RİSKİ ARASINDAKİ İLİŞKİ

Year 2022, Volume: 23 Issue: 4, 436 - 440, 17.10.2022

Mustafa Kuzeytemiz

https://doi.org/10.18229/kocatepetip.962183

Abstract

AMAÇ: Son zamanlarda ortaya çıkan koronavirüs (COVID-19) salgını, küresel bir halk sağlığı sorunu haline gelmiştir. Hipertansiyon, diabetes mellitus, obezite, kronik kalp ve akciğer hastalıkları, COVID-19 enfeksiyonu ve ciddi COVID-19 hastalığı gelişme riskini artırır. Bu çalışmada; hiperlipideminin tek başına COVID-19 enfeksiyonu gelişme riskini artırıp artırmadığını amaçladık.
GEREÇ VE YÖNTEM: Bu çalışmaya COVID-19 tanısı ile hastaneye yatırılan ve herhangi bir kronik hastalığı olmayan 134 hasta ile 122 sağlıklı kontrol alındı. Hasta grubunun başvurudan önceki son 6 aydaki lipid değerlerinin ortalaması hesaplandı. Kontrol grubunun da yine son 6 aylık lipid parametrelerinin ortalaması alındı.
BULGULAR: İki grup arasında yaş, cinsiyet ve laboratuvar özellikleri açısından fark yoktu. COVID-19 hastaları, kontrol deneklerine kıyasla önemli ölçüde daha yüksek trigliserit ve düşük yoğunluklu lipoprotein kolesterol değerlerine ve önemli ölçüde düşük yüksek yoğunluklu lipoprotein kolesterol seviyelerine sahipti (p <0.01).
SONUÇ: Dislipidemi ve COVID-19 ile ilgili mevcut araştırmalar sınırlı olmakla birlikte, bulgularımız serum kolesterol düzeylerinin COVID-19 gelişme riski ile önemli ölçüde ilişkili olduğunu göstermektedir.

Keywords

Covid-19 Virüs, Dislipidemi, Risk faktörleri

Supporting Institution

yok

THE RELATIONSHIP BETWEEN DYSLIPIDEMIA AND THE RISK OF COVID 19 INFECTION

Abstract

OBJECTIVE: The recent coronavirus disease 2019 (COVID-19) outbreak has become a worldwide public health problem. Hypertension, diabetes mellitus, obesity, chronic heart and lung diseases increase the risk of development of COVID-19 infection and severe COVID-19 disease. In this study; we aimed to investigate whether hyperlipidemia alone increases the risk of development of COVID-19 infection.
MATERIAL AND METHODS: One hundred-thirty four patients who were hospitalized with the diagnosis of COVID-19 and did not have any chronic disease and one hundred-twenty-two healthy controls were included in this study. The average of the lipid values of the patient group in the last 6 months before admission was calculated. Likewise, the average of the lipid parameters of the control group in the last 6 months was taken.
RESULTS: There were no differences between two groups with regard to age, gender, and laboratory characteristics. Triglyceride and Low-density lipoprotein cholesterol values were significantly higher and High-density lipoprotein cholesterol levels were significantly lower in the COVID-19 patients compared to the control subjects (p < 0.01).
CONCLUSIONS: Although research on the association of dyslipidemia with COVID-19 is still insufficient, our findings show that serum cholesterol levels are significantly associated with the risk of COVID-19 infection.

Keywords

Covid-19 Virus, Dyslipidemia, Risk factors

References

• 1. Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450-2.
• 2. Huang C, Wang Y, Li X, at al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
• 3. Heng L , Shang-Ming L , Xiao-Hua Y, et al. Coronavirus disease 2019 (COVID-19): current status and future perspective. Int J Antimicrob Agents. 2020;55(5):105951.
• 4. Yang J, Zheng Y, Gou X, et al Prevalence of comorbidities in the novel Wuhan coronavirus (COVID- 19) infection: a systematic review and meta- analysis. Int J Infect Dis. 2020;94:91-5.
• 5. Helms J, Tacquard C, Severac F, at al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089-98.
• 6. Zhonghua L, Xing B, Xue Z . The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. 2020;41(2):145-51.
• 7. Fan J, Wang H, Ye G, et al. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism. 2020;15:42-3.
• 8. Wei X, Zeng W, Su J, Et al. Hypolipidemia is associated with the severity of COVID-19. J Clin Lipidol. 2020;7:26-33.
• 9. Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem Biophys Res Commun. 2008;369:344-9.
• 10. Maiolino G, Rossitto G, Caielli P, et al. The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm. 2013;71:46-53.
• 11. Henry BM, Vikse J, Benoit S, et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167–73.
• 12. Yang M. SSRN Electronic Journal. Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection. 2020. https://papers.ssrn.com/sol3/ papers.cfm?abstract_id=3527420 Accessed April 10, 2020.
• 13. Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARS-CoV entry into 397 Vero E6 cells. Biochem Biophys Res Commun 2008;369:344-9.
• 14. Fan J, Wang H, Ye G, et al. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism 2020;15:42-3.
• 15. Wei X, Su J, Yang K, et al. Elevations of serum cancer biomarkers correlate with severity of COVID-19. J Med Virol. 2020;(12):45-51.
• 16. Li B, Yang J, Zhao F, et al. Prevalence 378 and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Re Cardiol. 2020;109:531- 8.
• 17. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.
• 18. Grudzinska FS, Dosanjh DP, Parekh D, et al. Statin therapy in patients with community-acquired pneumonia. Clin Med (Lond). 2017;17:403–7.
• 19. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory- confirmed influenza virus infections: a multistate study. J Infect Dis. 2012;205:13–9.
• 20. Mehrbod P, Omar AR, Hair-Bejo M, et al. Mechanisms of action and efficacy of statins against influenza. Biomed Res Int. 2014;87:63-70.